Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Deleted: Despite a significant down day for the S&P 500, shares of Cassava Sciences (NASDAQ: SAVA ) closed higher by 35%. That’s because the Securities and Exchange Commission (SEC) has closed its case on...
Summary Cassava Sciences increased by over 10% intraday on positive SEC news. Cassava Sciences is up 26% in the last month while the market is down 7%. Cassava Sciences is looking to produce what will one day potentially be the best-selling drug of all time. ...
Summary The second group of patients on simufilam on average experienced a .2 point decline in ADAS-Cog scores after one year. These results are similar to acetylcholinesterase inhibitors for mild Alzheimer's disease. Critics claim that some individuals in the first group who ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: JHVEPhoto / Shutterstock.com General Mills (NYSE: GIS ) stock is getting a boost on Wednesday after the food company increased its full-year guidance for fiscal 2023 . That updated guidance has Genera...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Sharaf Maksumov / Shutterstock.com Stitch Fix (NASDAQ: SFIX ) stock is taking a beating on Wednesday after the company released results for its fiscal fourth quarter of 2022 . The bad news for SFIX st...
The Cassava Sciences stock ( NASDAQ: SAVA ) has been very bullish over the past month. It has gained more than 58% in a span of 30 days and investors are still bullish on the stock. Yesterday, a whale with a lot of money to spend took a noticeably bullish stance on the SAVA st...
After a sharp selloff early this year, clinical-stage biotech Cassava Sciences ( NASDAQ: SAVA ) appears to be turning the tide, with its shares rising for the fourth straight session Friday on above-average volume to reach the highest level since April. Nearly 2.9M SAVA sh...
AUSTIN, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it has been invited to present a corporate overview at the H.C. Wainwright 24 th Annual Global Inve...
Summary Treatments such as Aricept and likely simufilam that inhibit the formation of the nitro-oxidant peroxynitrite and speed its decomposition stabilize Alzheimer's disease for about a year. Treatments (blarcamesine, Trappsol Cyclo, panax ginseng) that inhibit the formation of ...
Summary Multiple insiders have purchased shares on the open market in the last month. The company has now released positive 100 patient 12-month data. Another journal cleared the company of any wrongdoing. The SEC has officially ended any inquiries into the company. ...
News, Short Squeeze, Breakout and More Instantly...
Cassava Sciences, Inc. (NASDAQ: SAVA) is one of today's top gainers. The company's shares have moved 24.9% on the day to $12.59. Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...